Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 2
2012 2
2014 2
2015 3
2016 2
2017 1
2018 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

13 results
Results by year
Filters applied: . Clear all
Page 1
Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcgammaRIIIa-genotyped patients with previously treated follicular lymphoma.
Forero-Torres A, de Vos S, Pohlman BL, Pashkevich M, Cronier DM, Dang NH, Carpenter SP, Allan BW, Nelson JG, Slapak CA, Smith MR, Link BK, Wooldridge JE, Ganjoo KN. Forero-Torres A, et al. Clin Cancer Res. 2012 Mar 1;18(5):1395-403. doi: 10.1158/1078-0432.CCR-11-0850. Epub 2012 Jan 5. Clin Cancer Res. 2012. PMID: 22223529 Free article. Clinical Trial.
Cell binding assays showed AME-133v and rituximab competed for an overlapping epitope on the CD20 antigen, and AME-133v inhibited binding of biotinylated rituximab to CD20 in a concentration-dependent manner. AME-133v was well tolerated b …
Cell binding assays showed AME-133v and rituximab competed for an overlapping epitope on the CD20 antigen, and AME-1
Future therapies for pemphigus vulgaris: Rituximab and beyond.
Huang A, Madan RK, Levitt J. Huang A, et al. J Am Acad Dermatol. 2016 Apr;74(4):746-53. doi: 10.1016/j.jaad.2015.11.008. Epub 2016 Jan 11. J Am Acad Dermatol. 2016. PMID: 26792592 Review.
We review promising monoclonal antibodies, including veltuzumab, obinutuzumab (GA-101), ofatumumab, ocaratuzumab (AME-133v), PRO131921, and belimumab....
We review promising monoclonal antibodies, including veltuzumab, obinutuzumab (GA-101), ofatumumab, ocaratuzumab (AME-133v
Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies.
VanDerMeid KR, Elliott MR, Baran AM, Barr PM, Chu CC, Zent CS. VanDerMeid KR, et al. Cancer Immunol Res. 2018 Oct;6(10):1150-1160. doi: 10.1158/2326-6066.CIR-18-0319. Epub 2018 Aug 8. Cancer Immunol Res. 2018. PMID: 30089638 Free article.
ADCP and ADCC induction by rituximab, ofatumumab, obinutuzumab, or ocaratuzumab was measured using treatment-naive chronic lymphocytic leukemia (CLL) target cells and either human monocyte-derived macrophages (for ADCP) or natural killer (NK) cells (for ADCC). ...ADCP (0.5 …
ADCP and ADCC induction by rituximab, ofatumumab, obinutuzumab, or ocaratuzumab was measured using treatment-naive chronic lymphocyti …
New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T, Robak E. Robak T, et al. BioDrugs. 2011 Feb 1;25(1):13-25. doi: 10.2165/11539590-000000000-00000. BioDrugs. 2011. PMID: 21090841 Review.
The third-generation mAbs are also humanized mAbs, but in addition they have an engineered Fc to increase their binding affinity for the FcgammaRIIIa receptor. The third-generation mAbs include AME-133v, PRO131921 and GA-101. AME-133v (LY2469298) is a …
The third-generation mAbs are also humanized mAbs, but in addition they have an engineered Fc to increase their binding affinity for the Fcg …
Novel CD20 monoclonal antibodies for lymphoma therapy.
Cang S, Mukhi N, Wang K, Liu D. Cang S, et al. J Hematol Oncol. 2012 Oct 11;5:64. doi: 10.1186/1756-8722-5-64. J Hematol Oncol. 2012. PMID: 23057966 Free PMC article. Review.
This review will summarize the latest development in new mAbs against CD20, which include second-generation mAbs, ofatumumab, veltuzumab (IMMU-106), ocrelizumab (PRO70769), and third-generation mAbs, AME-133v (ocaratuzumab), PRO131921 and GA101 (obinutumumab) …
This review will summarize the latest development in new mAbs against CD20, which include second-generation mAbs, ofatumumab, veltuzumab (IM …
The future of CD20 monoclonal antibody therapy in B-cell malignancies.
Czuczman MS, Gregory SA. Czuczman MS, et al. Leuk Lymphoma. 2010 Jun;51(6):983-94. doi: 10.3109/10428191003717746. Leuk Lymphoma. 2010. PMID: 20367564 Review.
Preclinical and early clinical assessment of other novel anti-CD20 mAbs include: ocrelizumab, veltuzumab, GA101, AME-133v, and PRO131921; data suggest potential for improved efficacy over rituximab that will require substantiation in large-scale clinical trials. ...
Preclinical and early clinical assessment of other novel anti-CD20 mAbs include: ocrelizumab, veltuzumab, GA101, AME-133v, and …
Emerging immunological drugs for chronic lymphocytic leukemia.
Robak P, Smolewski P, Robak T. Robak P, et al. Expert Opin Emerg Drugs. 2015 Sep;20(3):423-47. doi: 10.1517/14728214.2015.1046432. Epub 2015 Jul 11. Expert Opin Emerg Drugs. 2015. PMID: 26153226 Review.
The search terms used were alemtuzumab, BI 836826, duvelisib ibrutinib, idelalisib, lenalidomide, monoclonal antibodies, MEDI-551, MOR208, obinutuzumab, ocaratuzumab, ofatumumab, ONO-4059, otlertuzumab, spebrutinib, veltuzumab and XmAb5574 in conjunction with CLL. ...
The search terms used were alemtuzumab, BI 836826, duvelisib ibrutinib, idelalisib, lenalidomide, monoclonal antibodies, MEDI-551, MOR208, o …
Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era.
Butler LA, Tam CS, Seymour JF. Butler LA, et al. Blood Rev. 2017 Sep;31(5):318-327. doi: 10.1016/j.blre.2017.05.002. Epub 2017 May 3. Blood Rev. 2017. PMID: 28499646 Review.
The addition of rituximab, ofatumumab and obinutuzumab to various chemotherapy regimens has led to considerable improvements in both response and survival. Ocaratuzumab, veltuzumab and ublituximab are currently being explored within the trial setting. ...
The addition of rituximab, ofatumumab and obinutuzumab to various chemotherapy regimens has led to considerable improvements in both respons …
Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages.
Church AK, VanDerMeid KR, Baig NA, Baran AM, Witzig TE, Nowakowski GS, Zent CS. Church AK, et al. Clin Exp Immunol. 2016 Jan;183(1):90-101. doi: 10.1111/cei.12697. Epub 2015 Oct 28. Clin Exp Immunol. 2016. PMID: 26307241 Free PMC article.
Next-generation anti-CD20 mAbs (ofatumumab, ublituximab, obinutuzumab, ocaratuzumab) were significantly more effective at inducing ADP compared to rituximab, but none were as effective as the anti-CD52 mAb alemtuzumab. ...
Next-generation anti-CD20 mAbs (ofatumumab, ublituximab, obinutuzumab, ocaratuzumab) were significantly more effective at inducing AD …
13 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page